


Amendments to the Claims

This Listing of Claims will replace all prior versions and listings in this application.

Listing of Claims

1. (Currently Amended) A compound represented by the formula:



or a prodrug, pharmaceutically acceptable salt or solvate thereof,

wherein, in the formula (1a), R_{1a} , R_{2a} , and R_3 - R_5 represent, each independently, hydrogen, halogen, lower alkyl that may be substituted, lower alkenyl that may be substituted, lower alkynyl that may be substituted, cycloalkyl that may be substituted, cycloalkenyl that may be substituted, cycloalkynyl that may be substituted, aryl that may be substituted, heterocyclic group that may be substituted, hydroxy, alkoxy that may be substituted, aryloxy that may be substituted, heterocyclic oxy that may be substituted, acyl that may be substituted, monosubstituted carbonyloxy that may be substituted, carbamoyl that may

be substituted, diazo, amidino that may be substituted, azido, nitroso, nitro, amino that may be substituted, imino that may be substituted, cyano, mercapto, monosubstituted thio that may be substituted, monosubstituted thioxy that may be substituted, monosubstituted sulfinyl that may be substituted, monosubstituted sulfonyl that may be substituted, sulfo, or trisubstituted silyl, and any combinations of R_{1a} , R_{2a} , R_3 - R_5 may together form a ring structure; provided that the following (i)-(x) are excluded:


- (i) a compound, wherein R_{1a} is hydrogen, OH, lower alkyl, cycloalkyl having a carbon number of 3-8, halogenated lower alkyl, or phenyl;

R_{2a} is hydrogen, lower alkoxy carbonyl, lower alkoxy, halogen, lower alkyl, cycloalkyl having a carbon number of 3-8, lower alkoxy carbonyl lower alkyl, carboxyl, carboxy lower alkyl, $-\text{CONHR}_6$ (R_6 : hydrogen; phenyl that may have a halogen atom, or lower alkyl), cyano; phenyl that may have a substituent selected from the group consisting of a hydroxyl group, halogen atom, lower alkyl group, lower alkoxy and phenylthio group; phenyl lower alkyl group that may have a substituent selected from the group consisting of hydroxyl group and lower alkoxy group on the phenyl ring; lower alkanoyloxy lower alkyl; benzoyl group; lower alkanoyl group that may have halogen atom; or hydroxy lower alkyl group that may have a substituent selected from the group consisting of a phenyl group and halogen atom;

R_3 is hydrogen, or OH;

R₄ is hydrogen, lower alkyl, lower alkoxy lower alkyl, or halogenated lower alkyl;

R₅ is



and

R₆ is hydrogen, lower alkyl, or lower alkoxy;

- (ii) a compound, wherein R_{1a} and R_{2a} are, each independently, hydrogen, halogen, CN, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino, or (substituted) phenyl; and

R₃ is (substituted) aryl, or (substituted) heteroaryl;


- (iii) a compound, wherein R_{1a} is hydrogen, (substituted) lower alkyl, cycloalkyl, thienyl, furyl, lower alkenyl, or (substituted) phenyl;

R_{2a} is hydrogen or lower alkyl; and

R₃ is amino that may be substituted;

- (iv) a compound, wherein R_{1a} is hydrogen, alkyl, OH, O-alkyl, halo, amino, or nitro;

R_{2a} is



wherein X is CH or N, and the nitrogen atom on the R_{2a} ring may be substituted;
and

R_3 and R_5 are, each independently, hydrogen, alkyl, alkenyl, alkynyl, aryl, halo, OH, or heterocyclyl;

- (v) a compound, wherein R_{1a} is hydrogen, alkyl, alkoxy, OH, halo, NO_2 , or NH_2 ;

R_{2a} is hydrogen, (substituted) alkyl, cycloalkyl, alkoxy, (substituted) alkenyl, (substituted) alkynyl, (substituted) aryl, (substituted) heterocyclyl, alkoxy-NRR, NO_2 , OH, NH_2 , or (substituted) heteroaryl;

R_3 and R_4 are, each independently, hydrogen, alkyl, aryl, cycloalkyl, OH, halo, amino, or nitro; and

R_5 is hydrogen, (substituted) alkyl, cycloalkyl, aryl, (substituted) heterocyclyl, halo, OH, or (substituted) heteroaryl;

- (vi) a compound, wherein R_{2a} is substituted acetyl, or heterocyclic-substituted lower alkylene or lower alkenylene; and

R_3 is phenyl that may be substituted;

- (vii) a compound, wherein R_{1a} and R_{2a} are each independently, hydrogen, halogen, (substituted) alkyl, (substituted) alkenyl, (substituted) aryl, (substituted) aralkyl, (substituted) heterocyclic group, or together form an alkylene group; and

R_3 is amino that may be substituted;

- (viii) a compound, wherein R_{1a} is hydrogen, alkyl, cycloalkyl, alkoxy, (alkyl)amino, aryl, or heteroaryl;

R_{2a} is hydrogen, alkyl, halogen, cyano, hydroxy, or alkoxy;

R_3 is amino that may be substituted, or alkoxy that may be substituted; and

R_5 is aryl;

- (ix) R_{1a} is lower alkyl that is substituted with a substituent selected from the group consisting of carboxy, lower alkoxycarboxy, and substituted carbamoyl;

R_{2a} is hydrogen;


R_3 is phenylcarbonylamino, wherein said phenyl group may be substituted; and

R_4 and R_5 are hydrogen; and

(x) (2, 5-dimethyl-pyrazolo-[1, 5-a]-pyrimidine-7-yl) succinic acid;

wherein the undefined substituents in the compounds (i)-(x) represent any substituents.

2. (Original) The compound of claim 1, wherein either one of R_{1a} and R_{2a} is hydrogen, and the other one is carbamoyl that may be substituted.
3. (Original) The compound of claim 1, represented by the formula:



or a prodrug, pharmaceutically acceptable salt or solvate thereof,

wherein, in the formula (I),

R_1 is hydrogen, lower alkyl, amino that may be substituted, or aryl lower alkyl that may be substituted; and

R₂ is hydrogen, lower alkyl that may be substituted, cycloalkyl that may be substituted, cycloalkyl lower alkyl that may be substituted, lower alkoxy that may be substituted, aryl that may be substituted, aryl lower alkyl that may be substituted, aryloxy lower alkyl that may be substituted, lower alkylsulfonyl that may be substituted, arylsulfonyl that may be substituted, heteroaryl lower alkyl that may be substituted, heterocyclic group lower alkyl that may be substituted, or amino that may be substituted; or


R₁ and R₂ together with the adjacent N atom may form a heterocycle that may be substituted;

R₃ is hydrogen, hydroxy, lower alkoxy, halogen, or amino that may be substituted;

R₄ is hydrogen, lower alkyl, or aryl that may be substituted; and

R₅ is hydroxy, lower alkyl that may be substituted, aryl that may be substituted, aryl lower alkyl that may be substituted, cycloalkyl lower alkyl that may be substituted, aryl lower alkenyl that may be substituted, cycloalkyl lower alkenyl that may be substituted, aryl lower alkynyl that may be substituted, cycloalkyl lower alkynyl that may be substituted, aryl carbonyl that may be substituted, aryl lower alkyl carbonyl that may be substituted, heterocyclic group that may be substituted, halogen, CHO, amino that may be substituted, or imino that may be


substituted; provided that a compound represented by the following formula is excluded:



wherein, in the formula (I'),

R₂' is hydrogen, phenyl that may be substituted with lower alkyl or halogen; R₃' is hydrogen or hydroxy; R₄' is hydrogen or lower alkyl; and R₅' is phenyl having phenylthio group that may further be substituted with lower alkyl or lower alkoxy.

4. (Original) The compound of claim 3 represented by the formula:



or a prodrug, pharmaceutically acceptable salt or solvate thereof,

wherein, in the formula (I-1), each substituent is defined above.


5. (Original) The compound of claim 3 or 4, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R₁ is hydrogen; and R₂ is aryl that may be substituted.
6. (Original) The compound of claim 3 or 4, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R₃ is hydrogen, or amino that may be substituted.
7. (Original) The compound of claim 3 or 4, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R₄ is hydrogen.
8. (Original) The compound of claim 3 or 4, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R₅ is aryl that may be substituted.
9. (Original) The compound of claim 3 or 4, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R₁ is hydrogen; R₂ is phenyl that may be substituted; R₃ is

hydrogen, or amino that may be substituted; R_4 is hydrogen; and R_5 is phenyl that may be substituted.

10. (Original) The compound of claim 9, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein the substituent on the phenyl in R_2 that may be substituted is one or more selected from the group consisting of heterocyclic group that may be substituted, lower alkyl carbonyl, cycloalkyl, lower alkyl, amino that may be substituted, halogen, halogenated lower alkyl, lower alkoxy, carboxy lower alkyloxy, heterocyclic group lower alkyloxy, amino lower alkyl, hydroxy, cyano, carbamoyl-heterocyclic group-oxy, cyano lower alkyl, and phenyl.
11. (Original) The compound of claim 10, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R_2 is heterocyclic group phenyl that may be substituted.
12. (Original) The compound of claim 10, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R_2 is piperazino phenyl that may be substituted, piperizino phenyl that may be substituted, or pyrrolidino phenyl that may be substituted.
13. (Original) The compound of claim 9, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein the substituent on the phenyl in R_5 that may be substituted is one or more selected from the group consisting of halogen, halogenated lower alkyl, aryl lower alkyloxy, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, phenyl, phenyloxy, phenyl lower alkyl, phenyl lower alkylamino, phenyl lower alkylthio, phenyl lower

alkenyl, phenyl carbamoyl, amino, cycloalkyl lower alkyloxy, and heteroaryl lower alkyloxy.


14. (Original) A pharmaceutical composition, comprising the compound of any one of claims 1-13.
15. (Original) A NAD(P)H oxydase inhibitor, comprising the compound of any one of claims 1-13.
16. (Original) A prophylactic or therapeutic agent for NAD(P)H-related diseases, comprising the compound of any one of claims 1-13.
17. (Original) The prophylactic or therapeutic agent of claim 16, wherein said disease is selected from the group consisting of inflammation, pulmonary circulation disorders, ischemic heart disease, cerebral circulation disorders, arteriosclerosis, diabetic complications, hypertension, and proliferative disorders.
18. (Original) The prophylactic or therapeutic agent of claim 16, wherein said disease is brain infarction or diabetic retinal disorder.
19. (Original) A NAD(P)H oxydase inhibitor, comprising a compound represented by the formula (Ia):



or a prodrug, pharmaceutically acceptable salt or solvate thereof,

wherein, in the formula, R_{1a}, R_{2a}, R₃-R₅ represent, each independently, hydrogen, halogen, lower alkyl that may be substituted, lower alkenyl that may be substituted, lower alkynyl that may be substituted, cycloalkyl that may be substituted, cycloalkenyl that may be substituted, cycloalkynyl that may be substituted, aryl that may be substituted, heterocyclic group that may be substituted, hydroxy, alkoxy that may be substituted, aryloxy that may be substituted, heterocyclic oxy that may be substituted, acyl that may be substituted, monosubstituted carbonyloxy that may be substituted, carbamoyl that may be substituted, diazo, amidino that may be substituted, azido, nitroso, nitro, amino that may be substituted, imino that may be substituted, cyano, mercapto, monosubstituted thio that may be substituted, monosubstituted thioxy that may be substituted, monosubstituted sulfinyl that may be substituted, monosubstituted sulfonyl that may be substituted, sulfo, or trisubstituted silyl, and any combinations of R_{1a}, R_{2a}, R₃-R₅ may together form a ring structure.

20. (Original) A NAD(P)H oxydase inhibitor, comprising a compound represented by the formula (I):



or a prodrug, pharmaceutically acceptable salt or solvate thereof,

wherein, in the formula,

R₁ is hydrogen, lower alkyl, amino that may be substituted, or aryl lower alkyl that may be substituted; and

R₂ is hydrogen, lower alkyl that may be substituted, cycloalkyl that may be substituted, cycloalkyl lower alkyl that may be substituted, lower alkoxy that may be substituted, aryl that may be substituted, aryl lower alkyl that may be substituted, aryloxy lower alkyl that may be substituted, lower alkylsulfonyl that may be substituted, arylsulfonyl that may be substituted, heteroaryl lower alkyl that may be substituted, heterocyclic group lower alkyl that may be substituted, or amino that may be substituted; or

R₁ and R₂ together with adjacent N atom may form a heterocycle that may be substituted;

R₃ is hydrogen, hydroxy, lower alkoxy, halogen, or amino that may be substituted;

R₄ is hydrogen, lower alkyl, or aryl that may be substituted; and

R₅ is hydroxy, lower alkyl that may be substituted, aryl that may be substituted, aryl lower alkyl that may be substituted, cycloalkyl lower alkyl that may be substituted, aryl lower alkenyl that may be substituted, cycloalkyl lower alkenyl that may be substituted, aryl lower alkynyl that may be substituted, cycloalkyl lower alkynyl that may be substituted, aryl carbonyl that may be substituted, aryl lower alkyl carbonyl that may be substituted, heterocyclic group that may be substituted, halogen, CHO, amino that may be substituted, or imino that may be substituted.

21. (Original) A method of preventing or treating NAD(P)H-related diseases, comprising administering the compound of any one of claims 1-20 to an animal including human.
22. (Original) The method of claim 21, wherein said disease is selected from the group consisting of inflammation, pulmonary circulation disorders, ischemic heart disease, cerebral circulation disorders, arteriosclerosis, diabetic complications, hypertension, and proliferative disorders.

23. (Original) The method of claim 21, wherein said disease is brain infarction or diabetic retinal disorder.
24. (Original) A use of the compound of any one of claims 1-20 for the manufacture of pharmaceuticals employed for preventing or treating NAD(P)H-related diseases.
25. (Original) The use of claim 24, wherein said disease is selected from the group consisting of inflammation, pulmonary circulation disorders, ischemic heart disease, cerebral circulation disorders, arteriosclerosis, diabetic complications, hypertension, and proliferative disorders.
26. (Original) The use of claim 24, wherein said disease is brain infarction or diabetic retinal disorder.
27. (Original) The compound of claim 1, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R_{1a} is carbamoyl that may be substituted.
28. (Original) The compound of claim 1, or a prodrug, pharmaceutically acceptable salt or solvate thereof, wherein R_{1a} is carbamoyl that may be substituted, and R_{2a} is hydrogen.
29. (Currently Amended) A medicament, comprising the compound of claim ~~claims~~-27 or 28
30. (Currently Amended) A NAD(P)H oxydase inhibitor, comprising the compound of claim ~~claims~~-27 or 28.